God is our Guide  Number 1 site for helping reverse diseases on Planet Earth
cidpUSA Foundation

 cidpusa.org   

      

 
Home
Diagnosis
Treatment
Pathology
Variants
CIDP info
Fibromyalgia
IVIG
 Anti-inflammatory Diet
Burning  Feet Home
Services Page
Chronic Fatigue
Autoimmune diseases
Prognosis
Bible healing
Celiac disease
Spinal Injury Green tea

CIDP articles

CIDP-neuropathy

Multi Focal Motor neuropathy

M.M.F.

Lewis Summer

Tips for CIDP

Axonal EMG

CIDP-EMG

Dr Katz -CIDP

Plasmapheresis

CIDP-INFO

CIDP-doctors

CIDP-Rituxan

CIDP-GBS-Handbook

CIDP-family issue

CIDP-Cyclosporin

Polyneuropathy

CIDP-GBS children

CIDP-Pork Plant

Peripheral Neuropathy

ALS & CIDP

Types of neuropathy

Treatment of alcoholic poly neuropathy

IgG subclass deficiency

IgG deficiency

Colostrum IgG

IgG subclass deficiency

IgG deficiency

Hallelujah Diet

Caveman Diet

Anticancer Diet

Ketogenic Diet

Myasthenia Diet

Natural Diet for diseases

Fat lowering Diet

Lower Cholesterol

Libido Diet

Homocysteine Lowering diet

Bible Diet

Hemodialysis Diet

Iodine deficient diet

Epilepsy diet

Food additives

No artificial sweetener in diet

Vinegar Benefits

Loss of apetitite

Breast cancer herbs

The best lifestyle

DeTox diet

Avoid Gum

Right Fat Diet

chemicals in French fries

Electrical Stimulation Therapy

Addison

Estrogen

DNA

Magnets and ageing

Quranic Shifa

Vitamin D Deficiency

Cupping

 

Natural Makeup
Neck Pain
Ocular Female diseases
Chronic fatigue syndrome
Osteoporosis
Women Heart Attacks
Spices
Cure all diseases
Vinegar
Memory problems
Breast Lymph Drainage
Kidney stone Buster
Bras cause breast cancer
Skin repair Clinic
Pandas
Hepatitis

 SubCutaneous IVIG  CIDP treatment CIDPUSA Foundation

   alternatives treatment of autoimmune disease read our e-book 

Special Medical Search

 

 Subcutaneous IVIg from the world leaders

Less side effects, no need of nursing personnel, infused by a automatic pump.

The levels of IgG in the blood are steady and less IVIG is required. This method is even useful in someone who is IGg deficient. IGIV means intravenous immune globulin but today new research has allowed this to be given by subcutaneous route for nearly all diseases. We help provide pump, IVIg , any where in the world by our pharmacy providers.

Home delivery IVIg  877-577-4844 for IVIg in USA or send email to info@cidpus.org (Pump & insurance auth provided)

subcutaneous needle inserted in tissue.
Subcutaneous IVIg infusion sets are available . these multi site subcutaneous administration sets  help speed up the subcutaneous infusion. A subcutaneous IVIg is available for infusion called Via

SCIG Delivery subcutaneous Sets are designed specifically for the administration of IgG (Immunoglobulin) where multiple infusion sites are needed.
The SCIG Infusion Set allows for multiple subcutaneous infusion sites connected to one common tube for connection to an infusion pump.

The SCIG Extension Set allows for connection to multiple needle sets while still allowing for connection to one common tube, for connection to an infusion pump.

 

Pediatric Asthma, Allergy & Immunology

Aseptic Meningitis Due to Intravenous Immunoglobulin Therapy That Resolved with Subcutaneous Administration
Dec 2000, Vol. 14, No. 4: 323-327

Michael R. Nelson, MD
Allergy-Immunology Department, Walter Reed Army Medical Center, Washington D.C.; Uniformed Services University of the Health Sciences, F. Edward Hebert School of Medicine, Bethesda, Maryland.
Allergy-Immunology Department, Walter Reed Army Medical Center, Washington D.C.; Uniformed Services University of the Health Sciences, F. Edward Hebert School of Medicine, Bethesda, Maryland.
Aseptic meningitis is a rare but well recognized severe complication of high-dose intravenous immunoglobulin (IVIG) therapy. We report the case of a 9-year-old female who presented with functional hypogammaglobulinemia and recurrent sinopulmonary infections refractory to antibiotic prophylaxis. She was started on replacement dose IVIG therapy that was complicated by the development of headache, nuchal rigidity, photophobia, fever, nausea, vomiting, and lethargy after most infusions. Clinical evaluation and two cerebrospinal fluid analyses were consistent with aseptic meningitis. Interventions such as slower rates, in-line filters, dilute preparations, manufacturer change, and pretreatment were largely ineffective. The addition of post-IVIG oral corticosteroids attenuated the severity of symptoms, but the patient's quality-of-life and school attendance continued to suffer. In light of a continued need for therapy, mounting intravenous access difficulties, and requirement for frequent high dose corticosteroids, a trial of subcutaneous immunoglobulin infusion was initiated. She has tolerated this therapy for more than 3 years without serious adverse effects or need for corticosteroids, and continues to achieve clinical benefit by this route. A recent rechallenge with IVIG resulted in recurrent symptoms. Disabling aseptic meningitis and severe headache are rare complications of replacement-dose IVIG. It is noteworthy that aseptic meningitis has been previously described for replacement IVIG therapy in only one other child, but the refractory nature of this side effect in the index case described is unique in the literature. Subcutaneous immunoglobulin infusion is an effective and well-tolerated alternative to IVIG, especially in the setting of recurrent aseptic meningitis. (Pediatr Asthma Allergy Immunol 2000;14[4]:323-327.

Standard IVIG infusion

 

Subcutaneous Infusion leads to a improved IgG level.

Above slides from Melvin Berger MD Case Western Reserve University

 

  Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs.

Gardulf A, Andersen V, Bjorkander J, Ericson D, Froland SS, Gustafson R, Hammarstrom L, Jacobsen MB, Jonsson E, Moller G, et al.

Department of Clinical Immunology, Karolinska Institute, Huddinge University Hospital, Sweden.

Immunoglobulins (IgG) as replacement therapy in primary antibody deficiencies can be given as intramuscular injections, or as intravenous or subcutaneous infusions. Our aims were to obtain information on the frequency of adverse systemic reactions during subcutaneous therapy, the occurrence and intensity of tissue reactions at the infusion sites, and serum IgG changes. Furthermore, we compared costs between the different replacement regimes. Our study included 165 patients (69 women, 96 men, aged 13-76 years) with primary hypogammaglobulinaemia or IgG-subclass deficiencies. Data were compiled from questionnaires filled in by the patients and from their medical records. 33,168 subcutaneous infusions (27,030 in home therapy) had been given. 106 (of which 16 were at home) adverse systemic reactions (100 mild, 6 moderate) were recorded in 28 patients (17%). No severe or anaphylactoid reactions occurred. Despite large immunoglobulin volumes given during 434 patient years (28,480 infusions), no signs have been found that indicate the transmission of hepatitis virus. Transient tissue reactions occurred at the infusion sites but were not troublesome to most patients and we found significant increases in mean serum IgG. The use of subcutaneous instead of intravenous infusions at home would reduce the yearly cost per patient for the health-care sector by US $10,100 in Sweden alone.
We conclude that subcutaneous administration of IgG is a safe and convenient method of providing immunoglobulins. We were able to reach serum IgG concentrations similar to those by the intravenous therapy and we found that the method could also be used successfully in patients with previous severe or anaphylactoid reactions to intramuscular injections.

--------------------------------

Immunoglobulin replacement treatment by rapid subcutaneous infusion

J Gaspar, B Gerritsen, A Jones

Department of Immunology, Great Ormond Street Hospital for Children NHS Trust, London WC1N 3JH, UK

Correspondence to: J Gaspar or A Jones.
Accepted 7 January 1998
 

Long term intravenous immunoglobulin (IVIG) infusion is an effective treatment for children with immunodeficiencies, but can be complicated by poor venous access, systemic adverse reactions, and the need for frequent hospital admission. Rapid subcutaneous immunoglobulin (SCIG) infusion has been found to be effective in adults with primary immunodeficiency. Twenty six children were treated with SCIG for a median period of two years (range six months to 3.5 years). Fifteen children had previously been treated with IVIG. Retrospective analysis showed that trough IgG concentrations while receiving SCIG were comparable with those while receiving IVIG during maintenance treatment. In severe hypogammaglobulinaemia, however, initial loading with SCIG or IVIG is probably indicated. During the treatment period there was no systemic adverse reaction nor severe reaction requiring admission to hospital. The subjective impression of all families was a significant improvement in the quality of life. This preliminary experience with SCIG in children suggests that it is an effective, convenient, and well tolerated alternative to intravenous treatment. Larger prospective studies are required to determine the place of SCIG in the management of immunodeficiencies.

Keywords: immunoglobulin; subcutaneous infusion; immunodeficiency

 

 

Some things have been said, yet so much more cannot be written about. See this message from God.